botimageai.com Open in urlscan Pro
141.193.213.21  Public Scan

Form analysis
1 forms found in the DOM

POST

<form id="mc4wp-form-1" class="mc4wp-form mc4wp-form-97" method="post" data-id="97" data-name="Newsletter">
  <div class="mc4wp-form-fields">
    <div class="newsletter-form">
      <input type="email" name="EMAIL" placeholder="Email Address*" required="">
      <div class="newsletter-btn-wrapper"><input type="submit" value="Subscribe"></div>
    </div>
  </div><label style="display: none !important;">Leave this field empty if you're human: <input type="text" name="_mc4wp_honeypot" value="" tabindex="-1" autocomplete="off"></label><input type="hidden" name="_mc4wp_timestamp"
    value="1722696270"><input type="hidden" name="_mc4wp_form_id" value="97"><input type="hidden" name="_mc4wp_form_element_id" value="mc4wp-form-1">
  <div class="mc4wp-response"></div>
</form>

Text Content

Dr. Randall W. Jones Bot Image

PR Announcement: ProstatID™
Dr. Randall W. Jones Bot Image
PR Announcement: ProstatID™
 * Home
 * About Bot Image™
 * Provider & Patient Guides
    * Prostate Cancer Detection With AI for Urologists, PCPs, and Imaging
      Centers
    * AI Prostate Cancer Screening & Diagnosis for Patients

 * ProstatID
 * Blogs, Publications & News
    * Blogs
    * News
    * Publications

 * Investor Relations
 * Contact Us

Contact Us


Menu


PIONEERING CANCER
DETECTION WITH
AI AND MRI (AND CT)





TRUSTED BY LEADING DOCTORS AND HOSPITALS






BOT IMAGE™, INC. HAS A FLAGSHIP PRODUCT AND PLANS FOR FUTURE APPLICATIONS.

At Bot Image™ AI, we’re on a mission to revolutionize medical imaging through
cutting-edge artificial intelligence technology. Our focus is on early detection
and precise diagnosis, with our flagship product, ProstatID™, leading the way in
the fight against prostate cancer. Explore ProstatID™ or future applications
here:

PROSTATID

Contact us for our Blue Ocean White Paper to learn more about the upcoming
future applications of our algorithm.



FUTURE APPLICATIONS

Contact us for our Blue Ocean White Paper to learn more about the upcoming
future applications of our algorithm.


BOT IMAGE, INC


PROSTATID IS NORTH AMERICA’S FIRST FDA-CLEARED PROSTATE CANCER SCREENING,
DETECTION AND DIAGNOSTIC AI SOFTWARE.

Explore ProstatID or future applications below:

VIDEOS & PHOTOS

Stay informed with our collection of articles, publications, and informative
texts detailing the impact of ProstatID™ and the advancements in AI-assisted
prostate cancer diagnosis.

ARTICLES & PUBLICATIONS

Stay informed with our collection of articles, publications, and informative
texts detailing the impact of ProstatID™ and the advancements in AI-assisted
prostate cancer diagnosis.

OUR EXPERTISE

Discover the expertise behind Bot Image™, Inc., the team of professionals
driving innovation in medical imaging, AI, and healthcare.

HOW IT WORKS

Explore a simplified explanation of ProstatID™ and its intricate AI algorithms,
providing insight into the technology revolutionizing prostate cancer detection.

DISCOVER OUR IMPACT

Learn firsthand about the impact ProstatID™ has had on patients’ lives through
testimonials and understand the positive changes our technology is bringing to
the world.

INVEST IN PROSTATID

Invest in the future of healthcare by becoming a part of Bot Image™, Inc.
Explore investment opportunities and be a driving force in the advancement of
medical imaging technology.

ABOUT BOT IMAGE, INC


LATEST PARTNERSHIPS

“We’re delighted to partner with Bot Image and to add their ProstatID solution
to our extensive AI portfolio,” said Ben Panter, Founder and CEO of Blackford.
“Bot Image’s commitment to the detection and management of prostate cancer is a
great fit with our mission to improve the lives of patients by leveraging AI to
drive healthcare efficiencies.”




ABOUT BOT IMAGE, INC


LATEST PARTNERSHIPS





ABOUT BOT IMAGE, INC


LATEST PARTNERSHIPS

ConcertAI’s TeraRecon adds AI-based accurate Prostate Cancer Screening and
Detection/Diagnosis into the Eureka Clinical AI Platform with Bot Image, Inc.
Partnership
by TeraRecon, on March 18, 2023

CAMBRIDGE, Mass., Mar. 18,2023  /PRNewswire/ — The Eureka Clinical AI platform,
from ConcertAI’s TeraRecon, now provides clinicians with the
state-of-the-art artificial intelligence and deep learning technology necessary
to bring Fast, effective, accurate Prostate Cancer Screening and
Detection/Diagnosis using bpMRI and AI to the masses through solutions from Bot
Image, Inc.





OUR FLAGSHIP PRODUCT


HOW PROSTATID WORKS



SCAN

Technologist performs standard screening or diagnostic MRI sequences and pushes
the study to their PACs with is Standard Operating Procedure. In parallel, they
push the study to the Platform partner of cloud service provider.

DETECT

ProstatID automatically detects study, sorts for necessary sequences, checks
quality, performs the detection and diagnosis and returns an appended series to
the unique patient ID with results and report to view in less than 5 minutes
typically = real-time diagnosis.

DIAGNOSE

This new series and report are appended to the study so that the radiologist
sees it along with all others on his/her viewing station; hence, no additional
effort, equipment or work to perform.

TREAT OR DON’T TREAT

ProstatID assists physicians with treatment planning by providing an entire view
of the organ highlighting all suspicious lesions with their individual risk
scores. Additionally, if lesion(s) are graded as high risk, they are presented
in two powerful 3D views within a transparent rendition of the prostate gland
giving interventionalists ideal cognitive targeting.

PAIN POINTS


WHY IS THERE A NEED FOR PROSTATID AND CANCER DETECTION?



INTERPRETING & READING

Interpreting Prostate MRI is very challenging and increases when the patient has
other conditions such as BPH (Benign Prostate Hyperplasia), Prostatitis, cysts,
etc.

Learn More

TIME-CONSUMING

Reading Prostate MRI is time-consuming while searching through stacks of 20-30
slices while simultaneously viewing corresponding slices of multiple series (ie,
T2W Axial, DWI, ADC) and cross-checking Coronal and Sagittal Views of T2W.

Learn More

HEALTHCARE AND PATIENT EXPENSE

Prostate MRI can be very expensive and time consuming using contrast agents.

Learn More

THE PROBLEM WITH NCCN GUIDELINES

out of date. Historically, the accuracy of radiological interpretation of
Prostate MRI has been less than stellar leading to a lack of confidence in the
prostate diagnostic space. Loss of confidence in MRI increased resistance to
adaptation of it by Urologists



Learn More

TODAY THERE IS A HUGE PARADIGM SHIFT

Bot Image’s Artificial Intelligence greatly improves diagnostic performance of
radiologists; provides a wholistic view of the entire prostate improving
treatment planning, patient discussions and targeting for interventionalists

Learn More


PROSTATID IS THE SOLUTION!



EASY

ProstatID outputs, physician’s can rely upon the color overlayed T2W image set
that indicate segmented lesions with their individual cancer risk score and read
through the noise of BPH, benign cysts, prostatitis, etc. This is because of the
software was trained to differentiate cancer on over 1000 biopsied cases and
with over 6000 biopsy points.

QUICK

ProstatID returns the detection and diagnostic results back to the sender
typically in less than 5 minutes; hence, the attending physician can begin
reading the study while the patient remains on the MRI table; thus, real-time
diagnostic assistance.

RAPID INTERPRETATION

Addressed: through clinical studies we have proven that we significantly improve
reader performance in early detection of prostate cancer. Our results show that
the addition of a boosted parallel random forest model-based CAD generated MRI
image series improves inter-reader agreement for PI-RADS classification and the
average detection performance for identification of clinically significant
prostate cancer among nine readers with varying experience levels in both
academic and nonacademic care settings.

PROSTATID


SOLUTION

A clinical study involving 150 prostate MRI studies from assorted MRI systems
and field strengths, all with biological (biopsy) ground truth points (pathology
verification) was conducted to measure the sensitivity/specificity of the
Software, ProstatID using a grid method for 3D location matching. The standalone
Performance of ProstatID is shown in the following AUROC curve
(sensitivity-specificity).




BOT IMAGE™’S PROSTATID AS A SAAS MEDICAL DEVICE AI SOFTWARE

Bot Image™’s ProstatID is also available as a SaaS medical device AI software
which requires very little time and effort to connect directly from the hospital
or imaging center PACS system to Bot Image™’s Cloud server.   The connection is
cyber secure and HIPAA compliant.  Furthermore, Bot Image™ does not process or
store PHI – only the Prostate MRI image sets including Axial T2W, DWI and ADC.  
Results are returned within a few minutes to the client’s PACS and the output of
the software, a post-processed copy of the T2W axial with the colorized overlay
indicating suspicious cancer lesions with their margins and risk score annotated
on the included PDF report.   NO ADDITIONAL EQUIPMENT, PHYSICIAN EFFORT OR
BUTTONS TO PUSH!   Reader simply selects the newly appended series that pops up
on the patient MRI viewer and reads the study concurrently with the AI output
assistance.


OUR EXPERTISE



AN OVERVIEW OF PROSTATE CANCER DETECTION STANDARD OF CARE AND THE ROLE OF MRI
FOR EARLY DETECTION OF PROSTATE CANCER

Randall W. Jones, D.Eng. (PhD, MBA) EARLY DETECTION through Screening
Population-Based Screening Studies Screening for Prostate Cancer (PCa) continues
to






THE USE OF PROSTATID IN CANCER DETECTION, DIAGNOSIS AND SCREENING

Overview: ProstatIDTM is North America’s first FDA-Cleared Prostate Cancer
SCREENING, Detection and Diagnostic AI software. With 94% AUROC (Area under






CONCERTAI’S TERARECON AND BOT IMAGE, INC. PARTNERSHIP 

 TeraRecon, on March 18, 2023 CAMBRIDGE, Mass., Mar. 18,2023  /PRNewswire/ — The
Eureka Clinical AI platform, from ConcertAI’s TeraRecon, now






OMAHA-BASED MRI MEDICAL DEVICE COMPANY, BOT IMAGE, RECEIVES FDA CLEARANCE FOR AI

FOR IMMEDIATE RELEASE Bot Image, an Omaha-based MRI medical device company has
developed an AI-driven medical device CAD software to…





About Bot Image™


TESTIMONIALS



“Without a doubt, every urologist dealing with prostate conditions should
incorporate ProstatID into their practice. Its indispensable role in improving
diagnostic accuracy and guiding therapeutic interventions makes it an
indispensable tool in the realm of urology. To forego the utilization of
ProstatID would be a disservice to both patients and practitioners alike.”



Testimonial

Dr. Russell Locke, M.D. Vantage Urologic Institute

“We are on board with ProstatID.  I feel more comfortable with this AI backing
me up.”
Dr. Woodhouse

“I have come to rely upon the ProstatID output to serve as my own Quality
control of interpretation, and it has paid off.”
Anonymous

“I use ProstatID on every case. I first look at all of the colorized suspect
lesions, 
then study them and make my diagnosis. Usually, I follow ProstatID
100%. 
ProstatID has been right-on with biopsy confirmation.”
Dr. Lynch Radiologist at Independent Imaging Center

“I’ve known Randy as a friend, a patient-advocate, and, yes-as a nerdy
physicist. His ingenuity and eye for the future are only matched by his
unflagging support for the health of humanity. This Software gives us a glimpse
of how empathy and technology can collide for the good of us all.”
Eric Walser, MD John Sealy Professor and Chairman of Radiology, The University
of Texas Medical Branch, Galveston, Texas

“I have the good fortune of knowing Randy (Randall W.) Jones for over twenty
years, through our shared interest in optimizing MRI for the care of men with
prostate cancer.  Over all these years, Randy has deeply impressed me with his
unflagging enthusiasm, innovation, and knowledge.  His passion for advancing
medical care continues to drive him forward as he pushes the envelope of imaging
technology, building on his unique blend of training, experience, and
entrepreneurship.”
Fergus Coakley, MD Professor and Chair, Diagnostic Radiology, OHSU, Portland

“In this wonderful book, Randy Jones articulates a story of success.  It’s a
triumph of creativity, science, and entrepreneurship.  This prostate cancer
survivor is a nonconformist that responds to challenges with inspiring thought,
candor, and conviction.  Through artificial intelligence, Jones has been able to
identify lesions in a way the world has yet to see and I’m confident th medical
field will endorse.  Ag great educational read from a brave American spirit.”
Dr. Fernando J. Bianco CEO Focalyx

“The problem with most translational science is that you seldom get good
feedback between the scientist and the end user.  By being relentless, actively
working on both ends of the process without the middlemen, and learning from
failures, he has achieved what no one else can.   Physicians are trained to
understand a complex system and work within it.   Randy reimagines the system
itself.  The Elon Musk of modern MRI development.”
Benjamin B. McDaniel, MD Radiologist, Syracuse, NY


VIEW INVESTMENT OPPORTUNITIES


View Investment Opportunities
slot malaysia


SUBSCRIBE TO OUR NEWSLETTER



Leave this field empty if you're human:


Copyright © 2024 Bot Image™, Inc. All Rights Reserved.
 * Privacy Policy
 * Terms & Conditions
 * Site Map

 * Home
 * About Bot Image™
 * Prostate Cancer Detection With AI for Urologists, PCPs, and Imaging Centers
 * AI Prostate Cancer Screening & Diagnosis for Patients
 * ProstatID™ – The FDA-Cleared AI Software for the Screening, Detection and
   Diagnosis of Prostate Cancer
 * Blogs, Articles & News
 * Investor Relations
 * Contact Us

LOCATION

Linden Place 14301 FNB Pkwy, Ste 109
Omaha, NE 68154

EMAIL ADDRESS

info@botimage.com
sales@botimage.com

PHONE NUMBER

402-334-2525


Close
 * Home
 * About Bot Image™
 * Provider & Patient Guides
   * Prostate Cancer Detection With AI for Urologists, PCPs, and Imaging Centers
   * AI Prostate Cancer Screening & Diagnosis for Patients
 * ProstatID
 * Blogs, Publications & News
   * Blogs
   * News
   * Publications
 * Investor Relations
 * Contact Us